Stocks · News reference
Cognition Therapeutics Q2 EPS $(0.04) Beats $(0.06) Estimate
Cognition Therapeutics (NASDAQ:CGTX) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.06) by 33.33 percent. This is a 63.64 percent increase over losses of $(0.11) per
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 6, 2026, 9:13 PM
- Checked
- Aug 6, 2026, 9:13 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
8-K filing — COGNITION THERAPEUTICS INC (CGTX)
Filed: 2026-06-24 AccNo: 0001104659-26-077060 Size: 218 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Read original at edgarCognition Therapeutics Receives Notice Of Allowance From USPTO For Patent Application 19/563,468, Covering Polymorphic Crystalline Form Of Zervimesine
Read original at benzinga